Company: VBI Vaccines Inc.
Job title: Chief Scientific Officer
Role of a Vaccine Immunotherapeutic in Combination Therapy to Achieve Functional Cure for Chronic HBV Infection 10:00 am
In addition to current NUCs and next-generation therapies, consensus is building that a functional cure for chronic HBV will also require the use of an immunotherapeutic to break immunological tolerance and restore long-term immunologic control over the virus. VBI’s vaccine immunotherapeutic candidate, VBI-2601 has been designed to restore and enhance T cell & B-cell immunity…Read more
day: Day Two